Highlight 3 in lung cancer
Professor Benjamin Besse, Head of the Cancer Medicine Department at Gustave Roussy and Chair of the EORTC Lung Group, meets with Dr. Mariana Brandao from the Hôpital Universitaire de Bruxelles – Institut Jules Bordet.
In this 15 minutes talk, they will delve deeper into the results of the CHRYSALIS-2 study, which is a phase 1/1b study that aims to evaluate the efficacy of amivantamabam + lazertinib in patients with EGFR-mutated NSCLC.
With the educational support of:
